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Summary Effective medicines exist to treat or alleviate many diseases which predominate in the developing
world and cause high mortality and morbidity rates. Price should not be an obstacle preventing access to
these medicines. Increasingly, drug donations have been established by drug companies, but these are
often limited in time, place or use. Measures exist which are more sustainable and will have a greater
positive impact on people's health. Principally, these are encouraging generic competition; adopting into
national legislation and implementing TRIPS safeguards to gain access to cheaper sources of drugs;
differential pricing; creating high volume or high demand through global and regional procurement;
and supporting the production of quality generic drugs by developing countries through voluntary
licenses if needed, and facilitating technology transfer.
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Introduction
Two billion people do not have regular access to life-saving
drugs or to those drugs which could vastly improve their
living conditions. For diseases affecting the rich and the
poor alike, prevalent in both developing and developed
countries, there is ongoing research, development and
production of effective drugs by the research-based
pharmaceutical industry. Frequently, however, the market
price of these drugs is so high that they are not affordable,
and therefore non-existent, for the great majority of people
in need. Drug price is not the only obstacle to access to
treatment, but it is clearly a major one.
The ®nal price of a drug for the end user is composed of
various factors, a signi®cant part originating from local
in¯uences such as import duties and tariffs; local taxes;
absence of national price control policy; and mark-ups for
wholesaling, distribution and dispensing. But the price set
by industry (manufacturing selling price) for new drugs is a
major part of the ®nal user price, especially for the public
health sector. It is the duty of states to implement health
systems to protect the health of their populations. Even the
poorest nations could better allocate their resources by
giving priority to the basic needs of their citizens. But
countries are as powerless as patients are when national
drug costs become the greatest fraction of their budget. For
some countries drugs can account for over half of the total
health budget.
The pricing policy of pharmaceutical companies is not
set according to the purchasing power of the different
countries, but follows a general strategy of maximizing
pro®t. Originator's drug prices are often equal, or more
expensive, in developing countries than in rich countries.
Such a pro®t-driven pricing policy further widens the
health gap between the rich and the poor. In many cases,
more affordable drugs are produced by the generic indus-
try, even for the most recent drugs. However, decision-
makers often do not have the information they need to
identify manufacturers who can supply these drugs. They
require easier access to comparative, updated prices.
This article summarizes recent price studies for drugs
used in the therapy of four diseases that predominate in the
developing world, and examines the possibilites available
to achieve greater drug access. The price differences among
the various manufacturers, the effect a price reduction
would have on countries with low health budgetary lines
and, in some cases, the effect drug donations have or could
have on these populations is presented.
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Leishmaniasis currently threatens 350 million people in 88
countries; 12 million people worldwide are believed to be
affected by the disease [World Health Organization
(WHO) 2000]. Visceral leishmaniasis (kala azar) is the
most severe form of the disease and, if left untreated, the
fatality rate is as high as 100%. Treatment for leishman-
iasis consists of pentavalent antimonial drugs administered
through daily intramuscular injections for a period of
30 days. Sodium stibogluconate (SSG), marketed as
Pentostam
Ò by Wellcome, is an old drug, off-patent, but
still expensive ($US 185 per patient treated). An alternative
generic drug, sodium antimony gluconate (SAG) (generic
sodium stibogluconate) is manufactured by Albert David
Ltd in Calcutta. It is widely used in India and Bangladesh
with reported cure rates of 95% (Chowdhury et al. 1991).
At $US 13 per patient SAG is 14 times cheaper than SSG.
For some time, these products were thought to be different
but a recent analysis has shown that SSG and SAG are
chemically identical (Veeken & Pe Âcoul 2000). Using Indian
SAG instead of SSG by Wellcome would allow any country
in need to treat 14 times more patients for the same cost.
All that is required is approval of SAG by the national drug
regulatory authority.
Trachoma
Trachoma is caused by the microorganism Chlamydia
trachomatis which provokes an in¯ammatory reaction in
the eye with formation of follicles in the conjunctiva. After
years of repeated infections, the inside of the eyelids may be
scarred so severely that the eyelid turns inwards with
eyelashes rubbing on the eyeball. If untreated, this condi-
tion leads to blindness. The disease is responsible for at
least 15% of the world's blindness; about 6 million people
are blinded by trachoma worldwide, most of these
irreversibly. If blindness is to be prevented, 146 million
active trachoma cases are estimated to be in need of
treatment (WHO 2000).
Tetracycline ointment is the basic treatment for
trachoma. Used since the 1950s, it is an effective drug that
is available at low cost. However, the treatment course,
lasting 6 weeks, is dif®cult to follow. A shorter treatment is
possible using the drug azithromycin, a macrolide with a
long average lifespan, administrated orally. According to
Tabbara et al. (1996) a single dose of azithromycin is as
effective as the 6-week daily course of tetracycline
ointment. The simpler treatment course makes oral
azithromycin much more effective for controlling trachoma
in communities (Schechter et al. 1999). However,
azithromycin has an enormous disadvantage compared
with tetracycline ointment: its cost. Although it was ®rst
developed in 1981 by a Croatian pharmaceutical company,
Pliva, exclusive sales rights were granted to P®zer for the
USA and Western Europe. In 1988 Pliva launched Sum-
mamed
Ò in central and eastern Europe, and in 1991 P®zer
launched Zithromax
Ò elsewhere. The patent will not
expire until 2005 in the USA and 2008 in other countries.
The price ®xed by P®zer is too high for those countries
where trachoma is endemic. One 250 mg capsule of
Zithromax
Ò costs around $US 4 in the USA, $US 2.17 in
Spain. There are, nonetheless, generic manufacturers in
countries without patent protection according to the
national patent law in force at the time the product was
®rst patented elsewhere. For instance, in India Cipla, an
internationally reputed company, sells its generic product
at one-sixth of the cost of the P®zer price ($US 0.37 per
250 mg capsule).
P®zer has participated in a programme to ®ght against
trachoma, including the donation of Zithromax
Ò for a
period of 2 years, within the International Trachoma
Initiative, as a part of the current comprehensive strategy
to eradicate trachoma, called SAFE. Five pilot countries
(Morocco, Vietnam, Ghana, Tanzania and Mali) have been
selected for this donation programme out of 16 priority
countries identi®ed by the WHO in Africa and Asia where
trachoma remains a major cause of blindness. Thanks to
this programme, the product has already reached some
populations in need. But who will provide treatment for
140 million active cases in dire need of this more effective
treatment? Which country, among the most affected by
trachoma, can afford P®zer's current price? Clearly it
would be better for countries to make tenders to all
producers to introduce market competition so that
countries could buy the quantities needed, eliminating
their dependence on gifts.
Cryptococcal meningitis
Cryptococcal meningitis, caused by Cryptococcus neofor-
mans, is the most frequent systemic fungal infection among
HIV-infected people. Without treatment life expectancy is
less than a month (UNAIDS 1998). On average this
opportunistic infection affects 9% of people living with
AIDS. In some countries the prevalence is much higher
(19% in Zaire, 20±25% in Thailand). Cryptococcosis is
relatively easy to diagnose. However, treatment and
secondary chemoprophylaxis are often impossible in
developing countries because of the high cost and limited
availability of the drugs required.
Fluconazole, recently included in the WHO Model List
for Essential Drugs, is one of the drugs recommended by
the WHO (WHO 1999) for treatment (induction phase and
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product, P®zer's Di¯ucan
Ò, remains expensive with prices
from private wholesalers ranging between $US 6.30 and
27.60 in different countries (Pe Ârez-Casas et al. 2000a,b).
Fluconazole was patented in 1982 by P®zer and the patent
will not expire before January 2004 in the US. In some
countries the patent is not recognized, because pharma-
ceutical products were not patentable according to their
national laws when P®zer was granted the patent. Cheaper
sources of ¯uconazole exist in Colombia, Spain, India and
Thailand. Generic ¯uconazole of equivalent quality is
produced, for instance, by a Thai company, Biolab, and
available at $US 0.29 per 200 mg capsule (Pe Ârez-Casas
et al. 2000b).
If South Africa, where ¯uconazole is under patent, could
import generic ¯uconazole from Thailand, the national
cost of treating 10 000 patients suffering from cryptococ-
cal meningitis would decrease from $US 29.70 million to
$US 1.04 million per year for maintenance treatment
(Pe Ârez-Casas et al. 2000a,b). In other words, each year,
with a given budget of $US 1.04 million, South Africa
would be able to treat 352 patients with P®zer's
¯uconazole and as many as 10 000 patients with generic
¯uconazole. This means 9648 additional lives saved each
year for the same budget. In March 2000, the Treatment
Action Campaign, a South African NGO, requested P®zer
to lower the price of ¯uconazole in South Africa or to grant
voluntary licences. This request was supported interna-
tionally by Me Âdecins sans Frontie Áres (MSF). P®zer
answered by announcing a donation that only began to
reach patients a year later.
HIV/AIDS
An estimated 36 million people are currently infected with
HIV worldwide, over 90% of whom live in the developing
world (UNAIDS 2000). The disease is now the single
leading cause of death in Africa. Antiretroviral (ARV)
drugs have decreased the AIDS-related mortality rate in the
USA by 75%, but the cost of these drugs is too high for the
majority of infected people. The most effective way to stop
the virus from advancing and to prevent resistances is a
combination of three drugs. However, the current cost for
this triple therapy is $US 10 000±15 000 per year per
patient if the originator's brand products are used.
Without patent protection, ARVs are much cheaper. In
Brazil pharmaceutical products were not patented until
1997 and most ARVs are produced locally. The average
price reduction thanks to the competition posed by generic
products, has been 79% up to last year (Figure 1), and the
prices continue to drop. This has enabled the Brazilian
government to give ARVs free of charge to all patients and
more than 90 000 people currently receive treatment. In
1999 this cost only 3% of the Ministry of Health's budget
and 0.06% of the country's GMP. In 2 years the Brazilian
government was able to save $US 472 million in treatment
of opportunistic diseases and hospital-related expenses.
Between 1996 and 1999 the mortality rate from AIDS
decreased by over 50% (Ministry of Health, Brazil, 2000).
Brazil is a middle-income country with a social security
system in place. In less developed countries external
funding would be needed to support the purchase of
drugs and the national AIDS programme. It is however,
clear that a similar or greater decrease in drug prices
would increase access to treatment and enable resources
to be better used.
There are other examples showing that generic compe-
tition leads to price reductions. A comparative study of
prices of AIDS drugs (Pe Ârez-Casas et al. 2000a) showed
that in the range of ARV prices under scrutiny, the lowest
price in developing countries is on average 85% less than in
the US because of the availability of generic products. If
Figure 1 Competition is highly effective in
reducing prices.
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generic product was included in the study, the average price
reduction is 90%. Prices were further reduced in February
2001 by generic companies in India, and the price of ARVs
has been falling continuously (Figure 2). In May 2000, the
biggest ®ve pharmaceutical companies offered price re-
ductions resulting in triple therapy costing around $US
1000. These reductions, however, have so far bene®ted only
a very small number of those affected by HIV/AIDS, and
even the discounted costs are higher than for some generic
drugs, with Indian generics companies offering around $ US
250 per patient per year. Some pharmaceutical laboratories
donate ARVs to developing countries, but these donations
are limited in time and are only addressed to certain
population groups. Boehringer Ingelheim, for instance,
donates neviparine, but only to prevent vertical
transmission.
Discussion: increasing access
Concerted international procurement efforts for vaccines
and contraceptives have been able to signi®cantly reduce
prices for these products, through a combination of
strategies. Prices of 1±5% of western market prices have
been achieved, with millions gaining access to these
products while pharmaceutical companies increased their
sales and re-importation to wealthier markets was pre-
vented. AIDS and other life-threatening diseases require
similar longer-lasting, more engaging solutions than the
current trend of discounts and drug donations with their
associated problems of sustainability, geographical and
quantitative restrictions, indication restrictions, time
restrictions and delays in implementation (Guilloux &
Moon 2000). No single strategy will be suf®cient to
achieve and sustain a real impact on access to vital drugs in
developing countries. Rather, a comprehensive system of
mutually supportive strategies is required.
Generic competition is one of the most powerful tools
that policy makers have to lower the price of drugs
sustainably. So far, it is the only proven way to bring drug
prices down. Information on drug prices worldwide is
scarce and should be gathered and made available to
developing countries. An inter-agency project (UNICEF
et al. 2001) has been established to improve information
about sources and prices of selected drugs and diagnostics
for HIV/AIDS. Similar comparative studies are needed for
other health areas.
Encouraging generic competition requires a pro public-
health interpretation of the World Trade Organization's
(WTO) agreement on Trade-Related Aspects of Intellectual
Property Rights (TRIPS) and active efforts by countries to
produce or import generics. Applying compulsory licensing
to import or locally produce generic versions of the
products needed, for instance, would guarantee a sustain-
able way to get cheaper drugs. Through parallel importing,
governments can also decrease the price of the patented
drugs needed by obtaining them at the lowest price offered
on the world market by the patent holder. Both safeguards,
as well as others included in the TRIPS agreement, should
be adopted into the national legislation (WHO 1997;
Correa 2000). Those countries where the TRIPS agreement
is not yet in force can bene®t from more affordable generic
drugs available in the world market as soon as these drugs
are approved by national pharmaceutical authorities.
Voluntary lowering of prices by the pharmaceutical
companies for low-income countries is a promising strat-
egy. Some aspects and regulations, such as preventing
lower-priced drugs from ¯owing back into high-income
markets, the scope of these reductions in terms of popu-
lations covered, diseases, and rate of discount applied,
require further elaboration. But thus far voluntary price
reductions for HIV/AIDS drugs have not been systematic;
rather, they appear to have largely been a public relations
response to political and international public pressure.
Figure 2 Impact of generic competition.
Sample AIDS triple-combination: lowest
world prices per patient per year (stavudine
+ lamivudine + nevirapine).
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by the WHO and other UN agencies with experience in
bulk purchase, would enable prices to be better negotiated
among all potential sources. This strategy has been
enormously successful for vaccines.
Technology transfer should be supported as well by
international organizations and national governments as a
way to guarantee the sustainable production of affordable
medicines.
Conclusions: towards equity pricing
Quality drugs for the treatment of diseases that are highly
prevalent and cause high mortality and morbidity in
developing countries are manufactured by different pro-
ducers. Choosing quality products that are sold at the best
prices would enable governments to protect their popula-
tions, reduce health-related expenses and, consequently,
help a larger number within their countries. Governments
of developed and developing countries, as the constituents
of intergovernmental bodies such as the WHO and the
WTO, are responsible for urging these agencies to look for
long-term solutions. Any new pricing policy for essential
medicines for developing countries must aim to achieve
equity pricing if it is to have real impact on the lives of
patients. Equity pricing is based on the principle that the
poor should pay less for, and have access to, life-saving,
essential medicines. The ®nal aim is to make essential drugs
available at a price that is fair, equitable and affordable for
all in need. Access to essential drugs should not be a luxury
of the privileged few. It is a matter of social equity and
justice.
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